Novel PET tracers for fibrogenesis and inflammation presented at Boulder Peptide Symposium

Antaros Tracer, a sister company to Antaros Medical dedicated to development of novel Positron Emission Tomography (PET) tracers, will have 2 abstract posters at the Boulder Peptide Symposium this week in Napa, California, September 18-21. The posters will show early data for new PET tracers developed for fibrogenesis and inflammation, respectively.

ATH001 as a tracer for fibrogenesis

Fibrosis can occur in almost any organ or tissue in the body and is a leading cause of morbidity and mortality. Current methods to assess fibrosis are either invasive or insufficiently sensitive for detecting ongoing fibrosis production (fibrogenesis). Thus, there is an unmet need for non-invasive and sensitive biomarkers that can help detect, stage, and elucidate the molecular processes that drive the pathology of fibrosis and enable the assessment of treatment effects in the search for novel antifibrotic drugs aiming to turn down fibrogenesis.

ATH001 is a tracer that is being developed to probe the presence of platelet-derived growth factor receptor beta (PDGFRβ). PDGFRβ is a marker of ongoing fibrogenesis in tissue. ATH001 enables tissue specific quantification of active fibrotic disease and shows strong promise as a non-invasive tool for imaging fibrogenesis and could provide valuable insights in the search for new treatments for fibrotic diseases. The details for this abstract can be found below.

Poster title: Affibody molecule ATH001 for tissue specific quantification of active fibrotic disease
Authors: Mitran B, Wegrzynlak O, Frejd F, Hagmar P, Wagner M, Korsgren O, Eriksson O

ATC001 as a tracer for inflammation

Inflammatory processes are an integral part in a wide range of diseases and there is a need for non-invasive tools to study immune processes to support the development of new therapies in inflammatory diseases involving activated immune cells including immuno-oncology, inflammatory bowel disease (IBD), rheumatoid arthritis (RA), and diabetes. Cluster of differentiation 69 (CD69) is a general surface marker for activated immune cells, and its upregulation can indicate ongoing tissue inflammation or infiltration of activated immune cells.

ATC001 has been developed as a PET tracer for quantitative, non-invasive assessment of inflammatory processes. The data presented in this poster looked at using ATC001 for early detection of infiltrating T-cells in solid tumours after therapy with immune checkpoint inhibition (ICI).

Poster title: Early detection of T-cell activation in immuno-oncology by ATC001 PET
Authors: Mitran B, Löfblom J, Stáhl S, Persson J, Hagmar P, Wagner M, Korsgren O, Eriksson O

You can see the full agenda for the Boulder Peptide Symposium here.

About Antaros Tracer

Antaros Tracer is a sister company to Antaros Medical, formed to ensure an expedited and focused development of new Positron Emission Tomography (PET) tracers to be used as important biomarkers in drug development studies. Current disease area focus is fibrotic disease and immune-system activation in immuno-oncology, inflammatory disease, and immunology.

Share on Linkedin Share on Twitter